吳瑩瑩 劉洪臣
糖尿病患者常導(dǎo)致多種器官的營(yíng)養(yǎng)不良性病變,在口腔中則可表現(xiàn)為糖尿病性牙齦炎和牙周炎;牙周炎是一類細(xì)菌感染性疾病,其危害不僅局限于口腔,隨著對(duì)其發(fā)病機(jī)制的深入研究,發(fā)現(xiàn)其與多種全身疾病均有密切關(guān)系。糖尿病與牙周炎之間是雙向關(guān)系,一方面糖尿病加重牙周炎的程度,另一方面牙周炎對(duì)糖尿病的代謝控制具有負(fù)面影響。牙周炎已被認(rèn)為是糖尿病的第六并發(fā)癥[1]。
糖尿病患者的血糖控制水平與牙周炎嚴(yán)重程度呈正相關(guān),血糖控制好的其骨吸收程度比血糖控制不良者輕[2]。研究還發(fā)現(xiàn)糖尿病患者牙周致病菌增多,這又使糖尿病患者牙周組織更易發(fā)生炎癥或加重原有炎癥[3]。異常的糖代謝也可以影響炎癥介質(zhì),高血糖狀態(tài)可導(dǎo)致形成一類非酶糖基化的蛋白質(zhì)和脂質(zhì),他們可與單核巨噬細(xì)胞表面高親和力受體結(jié)合,使其大量分泌TNF-α、IL等炎癥介質(zhì)[4]。TerVonen等[5]發(fā)現(xiàn)血糖控制良好的糖尿病患者有2.5%位點(diǎn)的牙周袋深度PD≥4mm,而血糖控制不良的有11.2%位點(diǎn)的牙周袋深度PD≥4mm。
糖尿病可增加牙周病的發(fā)病風(fēng)險(xiǎn)和加重牙周組織破壞程度。造成牙槽骨骨代謝的改變,使骨吸收活躍,骨形成緩慢,有骨質(zhì)疏松傾向。急性糖尿病早期抑制體外培養(yǎng)大鼠下頜骨成骨細(xì)胞基質(zhì)成熟和礦化[6]。動(dòng)物模型研究還發(fā)現(xiàn),糖尿病還可增加細(xì)胞凋亡,使成骨細(xì)胞、牙周膜纖維細(xì)胞減少[7]。糖尿病可引起持續(xù)更久的炎癥反應(yīng),更多的附著喪失,更嚴(yán)重的牙槽骨吸收,使骨修復(fù)能力明顯受損,妨礙新骨形成。動(dòng)物實(shí)驗(yàn)也證明高糖喂養(yǎng)的糖尿病大鼠在3周、健康大鼠9周均出現(xiàn)了上皮組織增生、結(jié)締組織和越隔纖維表層炎細(xì)胞浸潤(rùn)、牙槽骨吸收、深牙周袋形成,且隨時(shí)間延長(zhǎng)糖尿病大鼠較健康大鼠炎癥反應(yīng)加重[8]。
糖尿病可以加重牙周炎的嚴(yán)重程度,導(dǎo)致牙槽骨吸收增多,骨形成減少,發(fā)展過程受血糖水平、晚期糖基化終產(chǎn)物(AGEs)和各種炎癥介質(zhì)的調(diào)控[9,10]。
牙周炎所產(chǎn)生的促炎因子的合成和分泌增加,其增加不僅表現(xiàn)在局部的牙周組織和齦溝液中,還可以表現(xiàn)在患者的外周血中[11]。病變的牙周組織可成為全身炎癥介質(zhì)如TNF、IL-1β的一個(gè)儲(chǔ)蓄池。這些炎癥介質(zhì)進(jìn)入循環(huán)系統(tǒng),可引起局部或全身結(jié)締組織的破壞、血小板凝集、血栓栓塞,還可誘發(fā)急性期應(yīng)答,使C反應(yīng)蛋白水平明顯升高,這些蛋白質(zhì)可沉積于受損的血管壁,活化吞噬細(xì)胞,釋放氧化物[12]。
牙周炎可造成牙槽骨吸收及牙體松動(dòng)脫落,其病因除了菌斑牙石等局部因素外,還受到全身健康狀況的影響,而糖尿病就是高危因素之一。口腔中有多種細(xì)菌,其中有些細(xì)菌可產(chǎn)生毒素,這些毒素進(jìn)入血液之后,會(huì)使胰島素受體不能與胰島素結(jié)合,而導(dǎo)致血糖升高。嚴(yán)重的牙周炎與血糖控制不良有關(guān),并且會(huì)加重糖尿病引起的高血糖癥[13]。糖尿病患者伴發(fā)牙周炎時(shí),長(zhǎng)期的炎性因子刺激可使組織或細(xì)胞表面胰島素受體數(shù)目減少,活性降低,導(dǎo)致胰島素抵抗,從而使患者血糖水平難于控制[14]。牙周炎如果得到有效的治療,消除牙周感染,組織對(duì)胰島素的反應(yīng)會(huì)恢復(fù)正常,患者控制血糖所需的胰島素也就減少了[15]。
牙周病是指發(fā)生在牙支持組織(牙周組織)的疾病,包括僅累及牙齦組織的牙齦病和波及深層牙周組織(牙周膜、牙槽骨、牙骨質(zhì))的牙周炎兩大類。牙周炎是一種破壞性慢性炎癥疾病,其主要特征為牙周袋的形成及袋壁的炎癥,牙槽骨吸收和牙齒逐漸松動(dòng),它是導(dǎo)致成年人牙齒喪失的主要原因。
牙周炎的主要病理改變包括牙槽骨的吸收、牙周膜腔的增寬以及各種炎癥反應(yīng)的發(fā)生等。牙周炎病理改變不僅與致病菌及其毒性產(chǎn)物的作用相關(guān),還與機(jī)體在免疫應(yīng)答過程中產(chǎn)生的多種細(xì)胞因子(如IL-1,IL-6,IL-10等)的作用相關(guān)[16]。
白細(xì)胞介素(IL)-6是一種來源廣泛的多功能細(xì)胞因子,可由單核-吞噬細(xì)胞、成纖維細(xì)胞、上皮細(xì)胞、T細(xì)胞、成骨細(xì)胞等多種細(xì)胞分泌,是體內(nèi)復(fù)雜的細(xì)胞因子網(wǎng)絡(luò)中的關(guān)鍵成員,其功能可能與牙周炎的發(fā)生發(fā)展有關(guān)。IL-6的誘導(dǎo)因子包括牙周致病菌脂多糖(Lipopolysaccharides,LPS)、IL-1β、腫瘤壞死因子(TNF)-α等。在牙周炎癥過程中,IL-6不僅能激活中性粒細(xì)胞,而且還能延遲吞噬細(xì)胞對(duì)衰老和喪失功能的中性粒細(xì)胞的吞噬,從而加劇了炎癥介質(zhì)的產(chǎn)生;IL-6還可以誘導(dǎo)牙周組織中血管內(nèi)皮生長(zhǎng)因子的表達(dá),進(jìn)而促進(jìn)血管的生成,使組織內(nèi)的炎癥細(xì)胞及能量消耗增多,以加重炎癥反應(yīng)。牙周炎患者齦溝液中含有一定量的IL-6,并且其濃度與病變的嚴(yán)重程度之間具有一定的相關(guān)性[17]。Takahashi等[18]在牙周炎患者的齦溝液和牙根尖囊腫液中檢測(cè)到高水平的IL-6。Johnson等[19]發(fā)現(xiàn)牙周炎患者炎癥部位的IL-6的水平明顯增高。Andrea等[20]檢測(cè)了牙周炎患者的外周血發(fā)現(xiàn)牙周炎患者IL-6的水平比健康者高,經(jīng)過3個(gè)月的牙周治療后IL-6水平下降。
成纖維細(xì)胞是IL-6的主要來源,IL-6能抑制牙周膜細(xì)胞的生長(zhǎng),降低成纖維細(xì)胞的附著力,從而影響牙周膜的修復(fù)和代謝功能。岳玲等[21]研究發(fā)現(xiàn),IL-6不僅能夠抑制牙周膜細(xì)胞的生長(zhǎng),其抑制作用還呈時(shí)間和劑量依賴的關(guān)系。有學(xué)者用rIL-1β、LPS刺激培養(yǎng)的人牙齦成纖維細(xì)胞,發(fā)現(xiàn)培養(yǎng)的上清液中有大量高活性的IL-6[22]。
IL-6可以誘導(dǎo)成骨細(xì)胞產(chǎn)生破骨細(xì)胞分化因子及基質(zhì)金屬蛋白酶,前者可以誘導(dǎo)破骨細(xì)胞前體轉(zhuǎn)化為成熟的破骨細(xì)胞,后者則可以促進(jìn)骨基質(zhì)的降解。IL-6與IL-3協(xié)同作用,還可以促進(jìn)作為破骨細(xì)胞前體的骨髓干細(xì)胞和造血細(xì)胞的形成,并能促進(jìn)破骨細(xì)胞前體分化為成熟的破骨細(xì)胞。有研究認(rèn)為,IL-6是通過增加破骨細(xì)胞前體的數(shù)量來促進(jìn)甲狀旁腺激素介導(dǎo)的鈣和骨的吸收[23];認(rèn)為IL-6是通過與破骨細(xì)胞膜上表達(dá)的特異性受體結(jié)合來調(diào)控促進(jìn)骨的吸收。還有研究表明,IL-6具有抑制成骨作用,能輕度抑制成骨細(xì)胞堿性磷酸酶(ALP)的活性和膠原的合成,抑制骨吸收后新骨的形成[23,24]。有研究認(rèn)為,IL-6與牙槽骨吸收程度之間呈正相關(guān)關(guān)系[17]。Baker等[25]研究發(fā)現(xiàn)有IL-6基因表達(dá)的小鼠牙槽骨骨吸收量較無IL-6表達(dá)的小鼠明顯增加,表明IL-6參與了牙周病的炎癥反應(yīng),并與病變程度、骨吸收明顯相關(guān)。
IL-1是一種多功能的細(xì)胞因子,也是機(jī)體復(fù)雜的細(xì)胞因子網(wǎng)絡(luò)中的關(guān)鍵成員。單核巨噬細(xì)胞等多種細(xì)胞都能組成性的產(chǎn)生和/或在多種不同的刺激下反應(yīng)性地產(chǎn)生具有生物活性的IL-1。其能作用于幾乎所有類型的細(xì)胞,具有廣泛的生物學(xué)活性。IL-1家族包括IL-1α、IL-1β和IL-1受體拮抗劑。IL-1具有促炎作用,是牙周炎和牙槽骨吸收的重要致炎因子,還可誘導(dǎo)結(jié)締組織內(nèi)的間質(zhì)細(xì)胞產(chǎn)生金屬蛋白酶,促進(jìn)間質(zhì)中的膠原降解,為牙周組織中的主要破壞因子,與牙周炎的發(fā)生發(fā)展密切相關(guān)[26]。早在1991年,Stashenko等[27]發(fā)現(xiàn)IL-1β是牙周組織的主要IL-1的成分,且炎性牙齦組織中的IL-1β與牙周炎的活動(dòng)性密切相關(guān)。后來很多學(xué)者得出了一致的結(jié)論,牙周炎部位齦溝液中IL-1β的水平明顯高于健康部位。齦溝液中IL-1的水平受牙周炎嚴(yán)重程度的影響,牙周袋內(nèi)的IL-1濃度隨治療的成功而降低,其中IL-1β隨炎癥變化較為明顯[28]。
IL-1β對(duì)股骨的促吸收作用是IL-1α的13倍。研究證實(shí)IL-1β是已知體外骨吸收因子中活性最強(qiáng)的,且其骨吸收刺激作用具有劑量依賴性[29,30]。牙周膜成纖維細(xì)胞經(jīng)IL-1β作用后,其ALP基因表達(dá)信號(hào)顯著減弱,且此效應(yīng)隨IL-1β作用濃度加大和作用時(shí)間延長(zhǎng)而增強(qiáng)[31]。
目前,雖然人們對(duì)IL-1β在牙周炎發(fā)病過程中的認(rèn)識(shí)存在分歧,但都承認(rèn)在牙周炎癥部位的IL-1β含量較健康者顯著升高,并確認(rèn)IL-1β參與了牙周炎的病理過程。
TNF-α主要是由被革蘭氏陰性菌脂多糖激活的巨噬細(xì)胞所產(chǎn)生,對(duì)白細(xì)胞、血管內(nèi)皮細(xì)胞及結(jié)締組織中的各種細(xì)胞具有廣泛的生物學(xué)效應(yīng);還可激活前破骨細(xì)胞成熟為破骨細(xì)胞,促進(jìn)骨吸收;還可增強(qiáng)血管通透性,具有促炎作用。TNF-α在牙周炎發(fā)生發(fā)展過程中的主要作用是:作為始動(dòng)因子啟動(dòng)炎癥反應(yīng);增加破骨細(xì)胞的形成和活性,促進(jìn)牙槽骨的吸收;增加基質(zhì)金屬蛋白酶的產(chǎn)生,導(dǎo)致膠原纖維的破壞;刺激基質(zhì)細(xì)胞的凋亡,限制牙周組織的修復(fù)等。
在牙周炎患者炎癥牙齦和齦溝液中TNF-α水平明顯升高[32]。有研究證實(shí)IL-1β和TNF-α與多形核白細(xì)胞在牙周炎癥組織中浸潤(rùn)呈正反饋機(jī)制,其最終的結(jié)局是多形核白細(xì)胞的過度浸潤(rùn)與激活I(lǐng)L-1β和TNF-α的大量產(chǎn)生,這種惡性循環(huán)造成炎癥的擴(kuò)大與持續(xù)發(fā)展[26]。TNF可增強(qiáng)成纖維細(xì)胞產(chǎn)生IL-6。有研究將LPS和體外培養(yǎng)的人牙周膜細(xì)胞共同孵育,培養(yǎng)的上清液中可檢測(cè)到高水平的IL-6、TNF-α,說明牙周膜細(xì)胞可通過這種自分泌作用產(chǎn)生促炎因子,參與局部炎癥反應(yīng)[33]。TNF-α通過增加破骨細(xì)胞數(shù)量、減少骨基質(zhì)鈣化引起骨吸收。TNF-α可刺激包括牙周膜成纖維細(xì)胞產(chǎn)生膠原酶,導(dǎo)致組織破壞和骨吸收[34]。使用TNF-α拮抗劑可使骨喪失減少50%[35]。TNF-α促進(jìn)牙槽骨吸收過程的作用是通過破骨細(xì)胞實(shí)現(xiàn)的,但破骨細(xì)胞表面沒有TNF-α受體,因而TNF-α可能是通過作用于牙周膜內(nèi)其他細(xì)胞成分,使之進(jìn)一步作用于破骨細(xì)胞。有研究表明,TNF-α既可以通過誘導(dǎo)成骨細(xì)胞表達(dá)RANKL和M-CSF,間接地促進(jìn)破骨細(xì)胞的分化和功能,也可以直接促進(jìn)RANKL誘導(dǎo)的破骨細(xì)胞的形成和骨吸收活性增加[36,37]。IL-6與TNF-α具有協(xié)同作用,可相互促進(jìn)介導(dǎo)的骨吸收。
近年來,糖尿病發(fā)病機(jī)制的炎癥學(xué)說備受關(guān)注,認(rèn)為糖尿病是一種自然免疫和低度炎癥性疾病[38-41]。炎癥反應(yīng)及細(xì)胞因子參與了糖尿病的全過程,并與其發(fā)生發(fā)展密切相關(guān)[42]。研究證明大多糖尿病患者的免疫應(yīng)答一般顯示亢進(jìn)反應(yīng),其中很多患者體內(nèi)的炎癥介質(zhì)顯示分泌過剩的傾向。炎癥因子(如TNF-α、IL等),可導(dǎo)致胰島β細(xì)胞的損傷和死亡,進(jìn)而參與Ⅰ型糖尿病的發(fā)生[43]。Ⅱ型糖尿病患者TNF-α、IL-6的濃度較健康者顯著升高。有研究表明高濃度葡萄糖可誘導(dǎo)人單核細(xì)胞產(chǎn)生促骨吸收的細(xì)胞因子如IL-6和TNF-α。
研究證實(shí)脂肪細(xì)胞分泌的因子,如TNF-α、IL-6等參與了胰島素抵抗的產(chǎn)生并與其程度呈正相關(guān)[44]。學(xué)者研究了IL-1β、IL-6致糖尿病作用的影響,發(fā)現(xiàn)IL-1β可測(cè)得同時(shí)IL-6不增高者Ⅱ型糖尿病發(fā)病危險(xiǎn)性不增加;IL-1β低同時(shí)IL-6增高者預(yù)測(cè)Ⅱ型糖尿病的發(fā)生,即IL-1β在IL-6促Ⅱ型糖尿病的發(fā)生發(fā)展中,呈現(xiàn)允許作用[45]。IL-6受血糖調(diào)節(jié),高血糖可促進(jìn)胰島細(xì)胞分泌IL-6,而IL-6可促進(jìn)殺傷性T淋巴細(xì)胞過度激活,此作用與其他細(xì)胞毒作用可共同引起胰島β細(xì)胞死亡[46]。
炎癥因子還可以作用于胰島素信號(hào)轉(zhuǎn)導(dǎo)過程,影響胰島素的敏感性。在慢性炎癥狀態(tài)下,炎癥因子如TNF-α、IL等分泌增多,可通過加強(qiáng)胰島素受體底物(IRS)-1絲氨酸磷酸化,抑制胰島素受體酪氨酸磷酸化,從而減弱了胰島素的作用;還能降低葡萄糖裝運(yùn)蛋白(GLUT)-4mRNA表達(dá)水平,使胰島素刺激的葡萄糖轉(zhuǎn)運(yùn)功能降低[47]。
很多炎癥因子可以促進(jìn)骨吸收,研究證實(shí)TNF-α、IL-6與Ⅱ型糖尿病患者各部位骨密度呈顯著負(fù)相關(guān)性[48]。血清中TNF-α、IL-6與糖尿病骨質(zhì)疏松相關(guān)[49,50]。
[1]Loe,H.Periodontal disease.The sixth complication of diabetes mellitus[J].Diabetes Care,1993.16(1):329-334
[2]Diabetes and periodontal diseases.Committee on Research,Science and Therapy.American Academy of Periodontology[J].J Periodontol,2000.71(4):p.664-678
[3]Campus,G.,A.Salem,S.Uzzau,E.Baldoni,and G.Tonolo.Diabetes and periodontal disease:a case-control study[J].J Periodontol,2005.76(3):p.418-425
[4]Vlassara,H.,M.Brownlee,K.R.Manogue,C.A.Din arello,and A.Pasagian.Cachectin/TNF and IL-1 induced by glucose-modified proteins:role in normal tissue remodeling[J].Science,1988.240(4858):p.1546-1548
[5]de Pommereau,V.,C.Dargent-Pare,J.J.Robert,and M.Brion. Periodontalstatusin insulin-dependentdiabetic adolescents[J].J Clin Periodontol,1992.19(9 Pt 1):p.628-632
[6]吳 璇,劉洪臣,馬衛(wèi)東,鄂玲玲,王東勝.糖尿病大鼠下頜骨成骨細(xì)胞體外特性的研究[J].中華老年口腔醫(yī)學(xué)雜志,2008.2:p.97-100
[7]Liu,R.,H.S.Bal,T.Desta,N.Krothapalli,M.Alyassi,Q.Luan,and D.T.Graves.Diabetes enhances periodontal bone loss through enhanced resorption and diminished bone formation[J].J Dent Res,2006.85(6):p.510-514
[8]胡 琳,吳蘭雁,張舉之.糖尿病在大鼠實(shí)驗(yàn)性牙周炎發(fā)生中的作用[J].牙體牙髓牙周病學(xué)雜志,1995.3(5):p.1
[9]Graves DT,A.-M.H.,Liu R.Evidence that diabetes mellitus aggravates periodontal diseases and modifies the response to an oralpathogen in animalmodels[J].Compendium of continuing education in dentistry 2004.25(7 Suppl 1):p.38-45
[10]Liu R,B.H.,Desta T,Krothapalli N,Alyassi M,Luan Q,Graves DT.Diabetes enhances periodontal bone loss through enhanced resorption and diminished bone formation[J].Journal of dental research,2006.85(6):p.510-514
[11]Iacopino,A.and C.CW.Pathophysiological relationships between periodontitis and systemic disease:recent concepts involving serum lipids[J].Journal of Periodontology 2000.71:p.1375-1384
[12]Armitage,G.C.Periodontalinfectionsand cardiovascular dise ase--how strong is the association[J].Oral Dis,2000.6(6):p.335-350
[13]Kiran,M.,N.Arpak,E.Unsal,and M.F.Erdogan.The effect of improved periodontal health on metabolic control in type 2 diabetes mellitus[J].J Clin Periodontol,2005.32(3):p.266-272
[14]Taylor,G.W.,B.A.Burt,M.P.Becker,R.J.Genco,M.Shlossman,W.C.Knowler,and D.J.Pettitt.Severe periodontitis and risk for poor glycemic control in patients with non-insulin-dependent diabetes mellitus[J]. J Periodontol,1996.67(10 Suppl):p.1085-1093
[15]Miller,L.S.,M.A.Manwell,D.Newbold,M.E.Reding,A.Rasheed,J.Blodgett,and K.S.Kornman.The relationship between reduction in periodontal inflammation and diabetes control:a report of 9 cases[J].J Periodontol,1992.63(10):p.843-848
[16]PamelaJ.Baker,Mark Dixon,R.ToddEvans,LisaDufour,Ellis Johnson, D.C.o. CD4+ T Cells and the Proinflammatory Cytokines Gamma Interferon and Interleukin-6 Contribute to Alveolar Bone Loss in Mice Infection and Immunity,1999.67(6):p.2804-2809
[17]Geivelis M, T.D., Pederson ED. Measurements of interleukin-6 in gingival crevicular fluid from adults with destructive periodontal disease [J]. Journal of Periodontology,1993.64:p.980-983
[18]Takahashi K,T.S.,Nagai A,etal.Assessmentof interleukin-6 in the pathogenesis of periodontal disease[J].J Periodontol 1994.65(2):p.147-153
[19]Johnson,D.R.B.,F.G.Serio,and X.Dai.Vascular Endothelial Growth Factors and Progression of Periodontal Diseases[J].Journal of Periodontology,1999.70(8):p.848-852
[20]Marcaccini,A.M.,C.A.Meschiari,C.A.Sorgi,M.C.P.Saraiva, A.M.d. Souza, L.H. Faccioli, J.E.Tanus-Santos, A.B.N. Jr., and R.F. Gerlach.Circulating Interleukin-6 and High-Sensitivity C-Reactive Protein Decrease After Periodontal Therapy in Otherwise Healthy Subjects[J].Journal of Periodontology,2009.80(4):p.594-602
[21]岳 玲,肖明振,牛忠英.IL-6對(duì)人牙髓細(xì)胞、牙周膜細(xì)胞生長(zhǎng)影響的試驗(yàn)研究[J].牙體牙髓牙周病學(xué)雜志,1998.8(4):p.232-233
[22]P.Mark Bartold,D.R.H.Interleukin-6 production by human gingivalfibroblasts[J].Journalof Periodontal Research,1991.26(4):p.339-345
[23]Mata,J.D.L.,H.L.Uy,T.A.Guise,B.Story,B.F.Boyce, and G.R. Mundy. Interleukin-6 Enhances Hypercalcemia and Bone Resorption Mediated by Parathyroid Hormone-related Protein In Vivo[J].The Journal of Clinical Investigation,1995.95(6):p.2846-2852
[24]RJ,O.K.,T.LA,and S.D.Osteoclasts constitutively express regulators of bone resorption: an immunohistochemical and in situ hybridization study[J].Lab Invest 1997.76:457-465
[25]Baker,P.J.Genetic Control of the Immune Response in Pathogenesis[J].Journal of Periodontology,2005.76(11-s):2042-2046
[26]劉榮坤,曹采方,孟煥新,等.TNF-α及IL-1β與多形核白細(xì)胞在牙周炎癥組織中浸潤(rùn)的關(guān)系[J].中華口腔醫(yī)學(xué)雜志,2000.35(5):327-329
[27]Stashenko, P., P. Fujiyoshi, M.S. Obernesser, L.Prostak,A.D.Haffajee,and S.S.Socransky.Levels of interleukin 1β in tissue from sites of active periodontal disease[J].Journal of Clinical Periodontology,1991.18(7):548-554
[28]Barksby,H.E.,S.R.Lea,P.M.Preshaw,and J.J.Taylor.The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders[J].Clinicaland ExperimentalImmunology, 2007. 149:217-225
[29]Arend,W.P.The balance between IL-1 and IL-1Ra in disease[J].Cytokine&Growth Factor Reviews,2002.13(4):323-340
[30]Ishihara,Y.,T.Nishihara,T.Kuroyanagi,N.Shirozu,E.Yamagishi,M.Ohguchi,M.Koide,N.Ueda,K.Amano,and T.Noguchi.Gingival crevicular interleukin-1 and interleukin-1 receptor antagonist levels in periodontally healthy and diseased sites[J].Journalof Periodontal Research,1997.32(6):524-529
[31]牛忠英,史俊南,肖明振,等.IL-1β對(duì)HPLF堿性磷酸酶基因表達(dá)的影響[J].中華口腔醫(yī)學(xué)雜志,1993.28(2):73-74
[32]尹麗嬡,李.,潘亞萍,等.IL-lβmRNA、TNF-αmRNA在成人牙周炎患者牙齦組織中表達(dá)的研究[J].華西口腔醫(yī)學(xué)雜志,2001.19(5):318-320
[33]張鳳秋,吳織芬,萬(wàn)玲,袁乃梅.牙周優(yōu)勢(shì)菌內(nèi)毒素對(duì)人牙周膜細(xì)胞分泌IL-6、TNF-α的影響[J].牙體牙髓牙周病學(xué)雜志,2002.12(10):531-534
[34]Meikle,M.C.,S.J.Atkinson,R.V.Ward,G.Murphy,and J.J.Reynolds.Gingival fibroblasts degrade type I collagen films when stimulated with tumor necrosis factor and interleukin 1:Evidence that breakdown is mediated by metal loproteinases[J].Journal of Periodontal Research,1989.24(3):207-213
[35]Oates,T.W.,D.T.Graves,and D.L.Cochran.Clinical radiographic and biochemical assessement of IL-1/TNF-alpha antagonist inhibition of bone loss in experimental periodontitis [J].Journal of Clinical Periodontology,2002.29(2):137-143
[36]Kanzaki,H.,M.Chiba,I.Takahashi,N.Haruyama,M.Nishimura,and H.Mitani.Local OPG Gene Transfer to Periodontal Tissue Inhibits Orthodontic Tooth Movement[J].Journal of Dental Research 2004.83(12):.920-925
[37]Kanzaki,H.,M.Chiba,K.Arai, Takahashi,N.Haruyama,M.Nishimura,and H.Mitani.Local RANKL gene transfer to the periodontal tissue accelerates orthodontic tooth movement[J].Gene Therapy,2006.13:678-685
[38]Schmidt, M.I., B.B. Duncan, A.R. Sharrett, G.Lindberg,P.J.Savage,S.Offenbacher,M.I.Azambuja,R.P.Tracy,and G.Heiss.Markers of inflammation and prediction of diabetes mellitus in adults(Atherosclerosis Risk in Communities study):a cohort study[J].Lancet,1999.353(9165):1649-1652
[39]Pradhan,A.D.,J.E.Manson,N.Rifai,J.E.Buring,and P.M.Ridker.C-reactive protein,interleukin 6,and risk of developing type 2 diabetes mellitus[J].Jama,2001.286(3):327-334
[40]Vozarova,B.,C.Weyer,R.S.Lindsay,R.E.Pratley,C.Bogardus,and P.A.Tataranni.High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes[J].Diabetes,2002.51(2):455-461
[41]Pickup,J.C.and M.A.Crook.Is type II diabetes mellitus a disease of the innate immune system[J].?Diabetologia,1998.41(10):p.1241-1248
[42]張 幸.胰島素抵抗與2型糖尿病[J].中國(guó)醫(yī)藥研究,2005.3(1):45-48
[43]楊義生,陳家倫.脂肪組織分泌功能研究新進(jìn)展[J].中華糖尿病雜志,2004.12(3):205-208
[44]Fruhbeck,G.,J.Gomez-Ambrosi,F.J.Muruzabal,and M.A.Burrell.The adipocyte:a model for integration of endocrine and metabolic signaling in energy metabolism regulation[J].Am J Physiol Endocrinol Metab,2001.280(6):E827-847
[45]Spranger,J.,A.Kroke,M.Mohlig,K.Hoffmann,M.M.Bergmann,M.Ristow,H.Boeing,and A.F.Pfeiffer.Inflammatory cytokines and the risk to develop type 2 diabetes:results of the prospective population-based European Prospective Investigation into Cancer and Nutrition(EPIC)-Potsdam Study[J].Diabetes,2003.52(3):812-817
[46]Esposito,K.,F.Nappo,R.Marfella,G.Giugliano,F.Giugliano,M.Ciotola,L.Quagliaro,A.Ceriello,and D.Giugliano. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans:role of oxidative stress[J].Circulation,2002.106(16):2067-2072
[47]Rotter,V.,I.Nagaev,and U.Smith.Interleukin-6(IL-6)induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha,overexpressed in human fat cells from insulin-resistant subjects[J].J Biol Chem,2003.278(46):45777-45784
[48]M.E.Cohen-Solal,F.B.,O.Bernard-Poenaru,M.A.Denne,A.M.Graulet,M.BrazierandM.C.de Vernejoul.Increased Bone Resorbing Activity of Peripheral Monocyte Culture Supernatants in Elderly Women[J].The Journal of Clinical Endocrinology&Metabolism,1998.83(5):1687-1690
[49]RachońD,M.J.,Suchecka-RachońK,Semetkowska-Jurkie wicz B,Zorena K, ?ysiak-Szyd?owska W.Serum inte rleukin-6 levels and bone mineral density at the femoral neck in post-menopausal women with Type 1 diabetes[J].Diabetic medicine 2003.20(6):475-480
[50]Liu R,B.H.,Desta T,Behl Y,Graves DT.Tumor necrosis factor-alpha mediates diabetes-enhanced apoptosis of matrix-producing cells and impairs diabetic healing[J].The American journal of pathology,2006.168(3):757-764